Minerva Neurosciences Inc (NASDAQ:NERV) Expected to Announce Earnings of -$0.39 Per Share

Brokerages expect Minerva Neurosciences Inc (NASDAQ:NERV) to announce earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Minerva Neurosciences’ earnings, with estimates ranging from ($0.47) to ($0.30). Minerva Neurosciences reported earnings per share of ($0.31) in the same quarter last year, which would indicate a negative year over year growth rate of 25.8%. The business is expected to report its next quarterly earnings results on Monday, November 4th.

On average, analysts expect that Minerva Neurosciences will report full year earnings of ($1.50) per share for the current financial year, with EPS estimates ranging from ($1.68) to ($1.33). For the next fiscal year, analysts expect that the business will post earnings of ($2.53) per share, with EPS estimates ranging from ($3.31) to ($1.74). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.10.



NERV has been the topic of a number of recent analyst reports. ValuEngine raised Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Zacks Investment Research raised Minerva Neurosciences from a “hold” rating to a “strong-buy” rating and set a $7.75 price target on the stock in a research report on Friday, August 9th. HC Wainwright initiated coverage on Minerva Neurosciences in a research report on Friday, May 31st. They set a “buy” rating and a $22.00 price target on the stock. Finally, BidaskClub raised Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, August 23rd.

In related news, major shareholder Venture Associates L. Index III sold 110,818 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $4.41, for a total transaction of $488,707.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David Kupfer purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The shares were purchased at an average cost of $5.55 per share, for a total transaction of $55,500.00. Following the completion of the transaction, the director now owns 219,188 shares in the company, valued at approximately $1,216,493.40. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 413,736 shares of company stock worth $2,142,953. Corporate insiders own 12.00% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. TD Asset Management Inc. grew its position in shares of Minerva Neurosciences by 2.8% in the 2nd quarter. TD Asset Management Inc. now owns 58,847 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 1,600 shares during the last quarter. Bank of America Corp DE grew its position in shares of Minerva Neurosciences by 17.0% in the 4th quarter. Bank of America Corp DE now owns 20,412 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 2,963 shares during the last quarter. Alps Advisors Inc. grew its position in shares of Minerva Neurosciences by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 93,888 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 4,064 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Minerva Neurosciences by 63,940.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,404 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 6,394 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Minerva Neurosciences in the 2nd quarter worth approximately $54,000. 74.24% of the stock is currently owned by institutional investors and hedge funds.

Shares of NERV traded down $0.07 during trading on Friday, reaching $8.00. The company’s stock had a trading volume of 134,285 shares, compared to its average volume of 376,813. The company has a fifty day moving average of $6.89 and a two-hundred day moving average of $6.76. Minerva Neurosciences has a twelve month low of $4.07 and a twelve month high of $12.95. The company has a market cap of $312.20 million, a price-to-earnings ratio of -6.20 and a beta of 1.54.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Further Reading: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.